A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (CheckMate 9DX)
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Sponsor: Bristol-Myers Squibb
A PHASE3 clinical study on Hepatocellular Carcinoma and Liver Cancer, this trial is ongoing. The trial is conducted by Bristol-Myers Squibb and has accumulated 46 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
46 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 41 earlier versions
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
-
Feb 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
Dec 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
-
Nov 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Mar 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE3
-
Sep 2020 — Nov 2020 [monthly]
Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE3
-
Apr 2020 — Aug 2020 [monthly]
Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE3
-
Dec 2019 — Feb 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE3
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Apr 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — Apr 2018 [monthly]
Recruiting PHASE3
-
Jan 2018 — Mar 2018 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Ono Pharmaceutical Co. Ltd
For direct contact, visit the study record on ClinicalTrials.gov .